Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Insilico MedicineInsilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value ChainInsilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to...
- Robbins Geller Rudman & Dowd LLPHIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead the Hims & Hers Class Action LawsuitRobbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"), have until November 2, 2026 to seek appointment as...
- Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff DeadlineInvestors who lost money in CAPR after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung CancerRevolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS(ON) multi-selective inhibitor, in patients with previously treated advanced RAS mutant non-small cell lung cancer (NSCLC).
- BioRestorative Therapies Announces Reverse Stock SplitBioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company’s Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a certificate of change with the Secretary of State of the State of Nevada, which is expected to become effective as of 4:30 P.M. Eastern Time on September 7, 2026. The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the start of trading on September 8, 2026, under the symbol “BRTX” and under a new CUSIP number, 090655705. The Company is effecting the Reverse Stock Split with the intention of regaining compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
- SEIU Local 2“Kevin Quinn: Hold Dexterra Accountable”: SEIU Local 2 holds rally outside TransLink officeSkyTrain cleaners employed by Dexterra Group have been sounding the alarm about serious safety concerns about their jobs over the last several months. TransLink has refused to meet the workers despite repeated requests. Now, WorkSafeBC inspections have backed up workers’ concerns, with reports outlining several health and safety violations that are still outstanding.
- CodoxoCodoxo Named a Winner in 2026 Fierce AI Innovation AwardsAI-powered Point Zero Payment Integrity recognized for helping health plans prevent payment errors before claims are created. — Codoxo, the leading provider of AI and generative AI-powered healthcare payment integrity solutions, today announced...
- Dianthus Therapeutics, Inc. NEW YORK andDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on September 1, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
- NanochonNanochon Performs First Case in the Chondrograft™ First in Human Clinical StudyNanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the treatment of articular cartilage defects of the knee, today announced the successful treatment of the first patient in its First-in-Human (FIH)...
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that, in connection with the appointment of Jason V. O’Byrne as Chief Financial Officer effective August 11, 2026, the Company granted Mr. O’Byrne an employment inducement award consisting of stock options to purchase 650,000 shares of the Company’s common stock, with an effective grant date of September 1, 2026 and an exercise price of $10.56 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on September 1, 2026. The award was approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan. The stock options vest over four years, with 25 percent vesting on August 11, 2027 and the remainder vesting in 36 equal monthly installments over the following three years, subject to continuous employment as of such vesting dates.
- Xilio Therapeutics, Inc.Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
- Kaplan Fox & Kilsheimer LLP Alerts Hims & Hers Health, Inc. (NYSE: HIMS) Investors to a Securities Class Action Deadline on November 2, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors.